Privigen — the Simple, Sophisticated, Safe 10% Liquid IVIg Therapy

CSL Behring understands the needs of healthcare professionals and their patients, and shares their commitment to high standards of quality and safety. Discover why so many hospitals and pharmacies rely on Privigen, the perceptively different IVIg.

Privigen is approved by the FDA as a replacement therapy for primary immunodeficiency (PI). This includes, but is not limited to, humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. For patients with chronic ITP, Privigen can raise platelet counts.

Simple Administration and Storage

  • Ready-to-use 10% liquid intravenous immunoglobulin (IVIg), with no warming or reconstitution necessary
  • 36-month room-temperature storage saves refrigeration space
  • Supported by valuable healthcare professional and patient assistance services from CSL Behring
  • Simple storage: 40-g vial carton occupies less shelf space than two 20-g cartons for more efficient storage

Sophisticated Innovations in IVIg Therapy

  • First and only IVIg stabilized with proline
  • Contains NO sugar or preservatives, and only trace amounts of sodium
  • IgA ≤25 mcg/mL, IgG purity ≥98%
  • Single-call support from IgIQ, a comprehensive resource for distribution, coding, insurance, and general issues

Safe and Tolerable for Patients

  • Rigorous plasma testing, purification through precipitation and chromatography, 3-Step Virus Elimination and TSE Removal. Privigen is derived from human plasma. The risk of virus transmission cannot be completely eliminated
  • In clinical trials for primary immunodeficiency disease (PI), 97% of related adverse events were nonserious; 95% of 1038 infusions were administered without premedication.
  • In clinical trials for chronic immune thrombocytopenic purpura (ITP), adverse events were generally mild or moderate and typical of underlying disease and IVIg treatment. Privigen was well tolerated — 104 of 114 infusions were performed at the maximum permitted infusion rate.7
Home About Privigen About Privigen

Important Safety Information

Immune Globulin Intravenous (Human), 10% Liquid, Privigen®, is indicated as replacement therapy for patients with primary immunodeficiency (PI) associated with defects in humoral immunity, including but not limited to common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. Privigen is also indicated to raise platelet counts in patients with chronic immune thrombocytopenic purpura (ITP).


  • Thrombosis may occur with immune globulin products, including Privigen. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of human immune globulin intravenous (IGIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products that contain sucrose. Privigen does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction or renal failure, administer Privigen at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

See full prescribing information for complete boxed warning.

Privigen is contraindicated in patients with history of anaphylactic or severe systemic reaction to human immune globulin, in patients with hyperprolinemia, and in IgA-deficient patients with antibodies to IgA, who have had hypersensitivity reactions. Patients with IgA deficiency and antibodies to IgA are at greater risk of severe hypersensitivity and anaphylactic reactions.

In patients at risk for developing acute renal failure, monitor urine output and renal function, including blood urea nitrogen and serum creatinine; discontinue if renal function deteriorates. Ensure that patients with preexisting renal insufficiency or otherwise predisposed are not volume-depleted and administer Privigen at the minimum rate of infusion practicable.

Thrombosis might occur with Privigen, even in the absence of known risk factors. Patients could also experience hyperproteinemia, increased serum viscosity, or hyponatremia; infrequently, aseptic meningitis syndrome (AMS) may occur—more frequently with high doses (2 g/kg) and/or rapid infusion.

Hemolysis, either intravascular or due to enhanced red blood cell sequestration, can develop subsequent to treatment. Risk factors include non-O blood group, underlying inflammation, and high doses. Closely monitor patients for hemolysis and hemolytic anemia. Consider the relative risks and benefits before prescribing high-dose regimen for chronic ITP in patients at increased risk of thrombosis, hemolysis, acute kidney injury or volume overload. Monitor patients for pulmonary adverse reactions and signs of transfusion-related acute lung injury (TRALI).

Privigen is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical studies of patients being treated with Privigen for PI, the most common adverse reactions observed in >5% of subjects were headache, fatigue, nausea, chills, vomiting, back pain, pain, elevated body temperature, abdominal pain, diarrhea, cough, stomach discomfort, chest pain, joint swelling/effusion, influenza-like illness, pharyngolaryngeal pain, urticaria, and dizziness. Serious adverse reactions were hypersensitivity, chills, fatigue, dizziness, and increased body temperature.

In clinical studies of patients being treated with Privigen for chronic ITP, the most common adverse reactions seen in >5% of subjects were headache, elevated body temperature, positive DAT, anemia, nausea, epistaxis, vomiting, increases in conjugated and unconjugated bilirubin, decreased hematocrit, and increased blood lactate dehydrogenase. A serious adverse reaction was aseptic meningitis syndrome (AMS).

Treatment with Privigen might interfere with a patient’s response to live virus vaccines and could lead to misinterpretation of serologic testing. Use in pregnant women only if clearly needed. In patients over 65 or in any patient at risk of developing renal insufficiency, do not exceed recommended dose and infuse Privigen at the minimum rate practicable.

For more information about Privigen, please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

CSL Behring
© 2015 CSL Behring. The product information presented on this site is intended for US residents only. PVG/02-13-0014